

09/280020

Abstract of the Disclosure

PN
6-25-02

The present invention provides a method of treating Type I diabetes by administration of an effective amount of a glucagon-like peptide 1 or an ^{analogue}~~agonist~~ of glucagon-like peptide 1, either alone or in conjunction with a regimen of insulin administration.